drugset / Trial / NCT00299351

A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide.

NCT00299351

Phase 2 Unknown 8 enrolled Royal Marsden NHS Foundation Trust
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and tolerability of extended treatment with depsipeptide in patients who have at least demonstrated stable disease on prior Gloucester-sponsored depsipeptide clinical trials, and in the opinion of their physician/ investigator might benefit from continued treatment with depsipeptide

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Romidepsin Peptide